Paris, September 20, 2021 – UGGC Avocats, a leading business law firm, has supported Advent France Biotechnology (AFB), a venture capital firm specializing in life sciences seed capital, in the creation of Thabor Therapeutics, a start-up company aiming to develop an innovative therapeutic approach for patients with chronic inflammatory diseases.
Advent France Biotechnology (AFB), founded in 2016, invests in a variety of life science sectors, including drug discovery and new medical technologies. AFB has made 15 investments since the creation of its first fund in 2017, primarily in France, but also in Belgium, Spain and Ireland.
Thabor Therapeutics aims to develop innovations for patients with chronic inflammatory diseases, particularly IBD, affecting mucous membranes. Indications in other chronic inflammatory diseases of the digestive and pulmonary mucosa are also being studied.
The UGGC Avocats team that accompanied Advent France Biotechnology was composed of:
About UGGC Avocats
Founded in 1993, UGGC Avocats is one of the leading independent business law firms in France. UGGC Avocats assists private and public operators. The firm has extensive expertise in legal and tax matters; through its teams and its “family office”, it offers a very large capacity of intervention in France and internationally (Europe, Africa, Asia and South America). UGGC Avocats is positioned as a “client firm” and its approach is based on its ability to mobilize multidisciplinary teams adapted to its clients’ needs. UGGC Avocats is composed of more than 150 lawyers, including 33 partners.
Marine Dahais firstname.lastname@example.org +33 7 60 54 00 25
Anne Da Silva Passos email@example.com +33 7 60 53 99 28